<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A randomized trial was carried out comparing <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> (CsA) and short-term <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (MTX) versus CsA alone for <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft versus host disease</z:e> (GVHD) prophylaxis in patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA) undergoing allogeneic bone marrow transplantation (BMT) from a compatible sibling </plain></SENT>
<SENT sid="1" pm="."><plain>Seventy-one patients (median age, 19 years; range, 4-46 years) were randomized to receive either CsA and MTX or CsA alone for the first 3 weeks after BMT </plain></SENT>
<SENT sid="2" pm="."><plain>Subsequently, both groups received CsA orally, with gradual drug reduction until discontinuation 8 to 12 months after BMT </plain></SENT>
<SENT sid="3" pm="."><plain>Patients randomized in both arms had comparable characteristics and received the same preparative regimen (ie, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> 200 mg/kg over 4 days) </plain></SENT>
<SENT sid="4" pm="."><plain>The median time for neutrophil engraftment was 17 days (range, 11-31 days) and 12 days (range, 4-45 days) for patients in the CsA/MTX group and the CsA alone group, respectively (P =.01) </plain></SENT>
<SENT sid="5" pm="."><plain>No significant difference was observed in the probability of either grade 2, grade 3, or grade 4 <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD or <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD developing in the 2 groups </plain></SENT>
<SENT sid="6" pm="."><plain>The Kaplan-Meier estimates of 1-year transplantation-related mortality rates for patients given either CsA/MTX or CsA alone were 3% and 15%, respectively (P =.07) </plain></SENT>
<SENT sid="7" pm="."><plain>With a median follow-up of 48 months from BMT, the 5-year survival probability is 94% for patients in the CsA/MTX group and 78% for those in the CsA alone group (P = </plain></SENT>
<SENT sid="8" pm="."><plain>05) </plain></SENT>
<SENT sid="9" pm="."><plain>These data indicate that the use of CsA with MTX is associated with improved survival in patients with SAA who receive transplants from compatible siblings </plain></SENT>
<SENT sid="10" pm="."><plain>(Blood </plain></SENT>
<SENT sid="11" pm="."><plain>2000;96:1690-1697) </plain></SENT>
</text></document>